Connection

Kennerly Patrick to Central Nervous System Stimulants

This is a "connection" page, showing publications Kennerly Patrick has written about Central Nervous System Stimulants.
  1. Potential for Underestimation of d-Methylphenidate Bioavailability Using Chiral Derivatization/Gas Chromatography. Drug Metab Dispos. 2019 07; 47(7):764-767.
    View in: PubMed
    Score: 0.538
  2. The Clinical Pharmacokinetics of Amphetamines Utilized in the Treatment of Attention-Deficit/Hyperactivity Disorder. J Child Adolesc Psychopharmacol. 2017 Oct; 27(8):678-689.
    View in: PubMed
    Score: 0.481
  3. Comparative Ethanol-Induced Potentiation of Stimulatory Responses to Dexmethylphenidate Versus Methylphenidate. J Clin Psychopharmacol. 2015 Aug; 35(4):464-7.
    View in: PubMed
    Score: 0.415
  4. Isopropylphenidate: an ester homolog of methylphenidate with sustained and selective dopaminergic activity and reduced drug interaction liability. J Child Adolesc Psychopharmacol. 2013 Dec; 23(10):648-54.
    View in: PubMed
    Score: 0.369
  5. Transdermal and oral dl-methylphenidate-ethanol interactions in C57BL/6J mice: transesterification to ethylphenidate and elevation of d-methylphenidate concentrations. J Pharm Sci. 2011 Jul; 100(7):2966-78.
    View in: PubMed
    Score: 0.303
  6. Evolution of stimulants to treat ADHD: transdermal methylphenidate. Hum Psychopharmacol. 2009 Jan; 24(1):1-17.
    View in: PubMed
    Score: 0.263
  7. Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter? J Clin Psychopharmacol. 2008 Jun; 28(3 Suppl 2):S54-61.
    View in: PubMed
    Score: 0.253
  8. Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2007 Mar; 81(3):346-53.
    View in: PubMed
    Score: 0.232
  9. Methylphenidate and its ethanol transesterification metabolite ethylphenidate: brain disposition, monoamine transporters and motor activity. Behav Pharmacol. 2007 Feb; 18(1):39-51.
    View in: PubMed
    Score: 0.230
  10. Drug Regimen Individualization for Attention-Deficit/Hyperactivity Disorder: Guidance for Methylphenidate and Dexmethylphenidate Formulations. Pharmacotherapy. 2019 06; 39(6):677-688.
    View in: PubMed
    Score: 0.131
  11. The discriminative stimulus properties of methylphenidate in C57BL/6J mice. Behav Pharmacol. 2011 Feb; 22(1):14-22.
    View in: PubMed
    Score: 0.076
  12. Long-term consequences of methamphetamine exposure in young adults are exacerbated in glial cell line-derived neurotrophic factor heterozygous mice. J Neurosci. 2007 Aug 15; 27(33):8816-25.
    View in: PubMed
    Score: 0.060
  13. A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study. J Child Adolesc Psychopharmacol. 2006 Dec; 16(6):687-98.
    View in: PubMed
    Score: 0.057
  14. The role of the polymorphic efflux transporter P-glycoprotein on the brain accumulation of d-methylphenidate and d-amphetamine. Drug Metab Dispos. 2006 Jul; 34(7):1116-21.
    View in: PubMed
    Score: 0.055
  15. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults. Clin Pharmacokinet. 2003; 42(4):393-401.
    View in: PubMed
    Score: 0.043
  16. Ethanol Interactions With Dexmethylphenidate and dl-Methylphenidate Spheroidal Oral Drug Absorption Systems in Healthy Volunteers. J Clin Psychopharmacol. 2017 Aug; 37(4):419-428.
    View in: PubMed
    Score: 0.030
  17. Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am J Hum Genet. 2008 Jun; 82(6):1241-8.
    View in: PubMed
    Score: 0.016
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.